EP3464312A4 - Agents anti-trypanosomes et anti-leishmania pour animaux et humains - Google Patents

Agents anti-trypanosomes et anti-leishmania pour animaux et humains Download PDF

Info

Publication number
EP3464312A4
EP3464312A4 EP17807469.6A EP17807469A EP3464312A4 EP 3464312 A4 EP3464312 A4 EP 3464312A4 EP 17807469 A EP17807469 A EP 17807469A EP 3464312 A4 EP3464312 A4 EP 3464312A4
Authority
EP
European Patent Office
Prior art keywords
trypanosomonal
animal
leishmania
agents
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17807469.6A
Other languages
German (de)
English (en)
Other versions
EP3464312A1 (fr
Inventor
Stacie S. CANAN
Natalie Anne HAWRYLUK
Michael John Witty
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of EP3464312A1 publication Critical patent/EP3464312A1/fr
Publication of EP3464312A4 publication Critical patent/EP3464312A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/36—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing at least two amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/43—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C211/57—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/02—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/06—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C13/00—Cyclic hydrocarbons containing rings other than, or in addition to, six-membered aromatic rings
    • C07C13/02—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof
    • C07C13/08—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a five-membered ring
    • C07C13/10—Monocyclic hydrocarbons or acyclic hydrocarbon derivatives thereof with a five-membered ring with a cyclopentane ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP17807469.6A 2016-06-02 2017-06-01 Agents anti-trypanosomes et anti-leishmania pour animaux et humains Pending EP3464312A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344759P 2016-06-02 2016-06-02
PCT/US2017/035413 WO2017210408A1 (fr) 2016-06-02 2017-06-01 Agents anti-trypanosomes et anti-leishmania pour animaux et humains

Publications (2)

Publication Number Publication Date
EP3464312A1 EP3464312A1 (fr) 2019-04-10
EP3464312A4 true EP3464312A4 (fr) 2019-11-27

Family

ID=60477945

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17807469.6A Pending EP3464312A4 (fr) 2016-06-02 2017-06-01 Agents anti-trypanosomes et anti-leishmania pour animaux et humains

Country Status (7)

Country Link
US (2) US10010555B2 (fr)
EP (1) EP3464312A4 (fr)
JP (1) JP6949057B2 (fr)
CN (1) CN109476696B (fr)
AR (1) AR108665A1 (fr)
TW (1) TW201802093A (fr)
WO (1) WO2017210408A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3464287B1 (fr) 2016-06-02 2022-06-08 Celgene Corporation Agents anti-paludéens pour animaux et humains
WO2022002118A1 (fr) * 2020-07-01 2022-01-06 四川海思科制药有限公司 Dérivé hétérocyclique à cycles fusionnés et son utilisation médicale

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007135380A2 (fr) * 2006-05-24 2007-11-29 Medical Research Council Composés et compositions antiparasites
US20080021048A1 (en) * 2005-01-13 2008-01-24 Bennett Brydon L Methods of treatment and prevention using haloaryl substituted aminopurines
WO2014135245A1 (fr) * 2013-03-05 2014-09-12 Merck Patent Gmbh Dérivés de 9-(aryl ou hétéroaryl)-2-(pyrazolyl, pyrrolidinyl ou cyclopentyl)aminopurine utilisés en tant qu'agents anticancéreux

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4914086A (en) * 1987-12-18 1990-04-03 University Patents, Inc. Method for treating African human and veterinary trypanosomiases
DK120892D0 (da) * 1992-09-30 1992-09-30 Statens Seruminstitut Treatment and prophylaxis of diseases caused by parasites, fungi or bacteria
US5773424A (en) * 1994-12-16 1998-06-30 Research Corporation Technologies, Inc. Treatment of toxoplasmosis
PE20020506A1 (es) * 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US20080187575A1 (en) * 2004-08-27 2008-08-07 Bert Klebl Pyrimidine Derivatives
US7521446B2 (en) 2005-01-13 2009-04-21 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
US7723340B2 (en) * 2005-01-13 2010-05-25 Signal Pharmaceuticals, Llc Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
NZ589053A (en) 2006-10-27 2012-03-30 Signal Pharm Llc Process of preparing 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol compounds
US20100056494A1 (en) * 2007-01-26 2010-03-04 Irm Llc Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
AU2008307798B2 (en) * 2007-10-05 2013-10-03 Verastem, Inc. Pyrimidine substituted purine derivatives
WO2009143865A1 (fr) * 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
UA103195C2 (uk) * 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
JP5785078B2 (ja) * 2008-08-11 2015-09-24 グラクソスミスクライン エルエルシー 新規アデニン誘導体
WO2010059418A1 (fr) * 2008-11-19 2010-05-27 The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services Composés de triazine et de purine substituées, méthodes d'inhibition de cruzaïne et de rhodésaïne et méthodes de traitement de la maladie de chagas et de la trypanosomiase africaine
WO2013166545A2 (fr) * 2012-05-07 2013-11-14 The University Of Queensland Inhibiteurs de 6-oxopurine phosphoribosyltransférase
US9233961B2 (en) * 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN113248506A (zh) * 2014-10-06 2021-08-13 西格诺药品有限公司 取代的氨基嘌呤化合物、其组合物及其治疗方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080021048A1 (en) * 2005-01-13 2008-01-24 Bennett Brydon L Methods of treatment and prevention using haloaryl substituted aminopurines
WO2007135380A2 (fr) * 2006-05-24 2007-11-29 Medical Research Council Composés et compositions antiparasites
WO2014135245A1 (fr) * 2013-03-05 2014-09-12 Merck Patent Gmbh Dérivés de 9-(aryl ou hétéroaryl)-2-(pyrazolyl, pyrrolidinyl ou cyclopentyl)aminopurine utilisés en tant qu'agents anticancéreux

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017210408A1 *

Also Published As

Publication number Publication date
AR108665A1 (es) 2018-09-12
JP2019517500A (ja) 2019-06-24
WO2017210408A1 (fr) 2017-12-07
EP3464312A1 (fr) 2019-04-10
TW201802093A (zh) 2018-01-16
CN109476696B (zh) 2022-06-10
JP6949057B2 (ja) 2021-10-13
CN109476696A (zh) 2019-03-15
US20170348315A1 (en) 2017-12-07
US20180280399A1 (en) 2018-10-04
US10010555B2 (en) 2018-07-03
US10420772B2 (en) 2019-09-24

Similar Documents

Publication Publication Date Title
EP3529279A4 (fr) Agents de liaison à cd133 et leurs utilisations
EP3303379A4 (fr) Agents de liaison à tigit et leurs utilisations
AU201710083S (en) Bowl and Covered Bowl
EP3720502A4 (fr) Produits cytobiologiques et leurs utilisations thérapeutiques
EP3253890A4 (fr) Agents de liaison à la tnfrsf et leurs utilisations
EP3362479A4 (fr) Agents de type anticorps spécifiques de l'antigène cd19 humain et leurs utilisations
EP3244727A4 (fr) Protéines insecticides et leurs procédés d'utilisation
EP3389369A4 (fr) Système de surveillance environnementale et physiologique d'animaux
ZA201805805B (en) Formulations and methods
ZA201806436B (en) Insecticidal proteins and methods for their use
EP3324967A4 (fr) Formulations à base de pridopidine et utilisation desdites formulations
EP3633034A4 (fr) PROTÉINE Cas9 MODIFIÉE, ET APPLICATION ASSOCIÉE
EP3250589A4 (fr) Agents diagnostiques et thérapeutiques
EP3534910A4 (fr) Procédés et agents thérapeutiques
ZA201907063B (en) Insecticidal proteins and methods for their use
EP3349592A4 (fr) Formulation d'os à mâcher pour animal et son procédé de fabrication
EP3749691A4 (fr) Agents de liaison à angptl8 et leurs méthodes d'utilisation
GB201709840D0 (en) Methods and medical uses
EP3378328A4 (fr) Agent fortifiant pour nutrition animale et son application
IL267278B (en) A system for eliminating insects and its use
EP3493669A4 (fr) Fer à cheval et fixations pour fer à cheval
EP3409211A4 (fr) Implant et élément de fixation
EP3464312A4 (fr) Agents anti-trypanosomes et anti-leishmania pour animaux et humains
EP3302530A4 (fr) Agents thérapeutiques à base de cdh26 et leur utilisation
EP3267796A4 (fr) Combinaisons de pip-72 insecticides et procédés d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20181128

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20191028

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/11 20060101ALI20191022BHEP

Ipc: C07H 21/02 20060101AFI20191022BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220307

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CELGENE CORPORATION